COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals ...

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

In a European study, higher consumption of fruits, vegetables, legumes, and potatoes was associated with a reduced risk of ...

These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...

By Siddhi Mahatole and Puyaan Singh (Reuters) -INmune Bio said on Monday its experimental Alzheimer's drug failed to improve ...

A federal judge has rejected Johnson & Johnson’s challenge to block its proposed rebate model under the 340B Drug Pricing Program, Bloomberg Law reported June 27. Judge Rudolph Contreras of the U.S.

Although anti-calcitonin gene-related peptides are safe and efficacious for adolescents with chronic migraine, access to ...

Lifestyle therapy may not be enough to improve outcomes for patients with HF and obesity, but careful risk evaluation and ...